ViaLase and Moran Eye Center Partner to Advance Glaucoma Research and Innovation

ViaLase和Moran眼科中心合作伙伴推进青光眼研究和创新

December 11, 2024

2024年12月11日

ViaLase has announced a groundbreaking research partnership with the John A. Moran Eye Center at the University of Utah, home to the Alan S. Crandall Center for Glaucoma Innovation. This collaboration aims to accelerate glaucoma research by utilizing Moran’s state-of-the-art iPerfusion technology to study the effects of ViaLase’s innovative femtosecond laser procedure..

ViaLase宣布与犹他大学约翰·莫兰眼科中心（JohnA.MoranEyeCenter）建立了开创性的研究伙伴关系，该中心是艾伦·S·克兰德尔青光眼创新中心（AlanSCrandall Center for Glaucoma Innovation）的所在地。这项合作旨在通过利用Moran最先进的iPerfusion技术来研究ViaLase创新的飞秒激光程序的效果，从而加速青光眼的研究。。

Exploring the ViaLase Laser Procedure

探索ViaLase激光程序

The ViaLase laser procedure employs femtosecond laser pulses with micron-accurate image guidance to create precise apertures through the trabecular meshwork (TM) into Schlemm’s canal. This innovative approach targets the conventional outflow pathway to enhance the drainage of aqueous humor, a critical factor in reducing intraocular pressure (IOP) for glaucoma management..

ViaLase激光程序使用飞秒激光脉冲和微米级精确图像引导，通过小梁网（TM）创建精确的孔径进入Schlemm管。这种创新的方法针对传统的流出途径，以增强房水的引流，房水是降低青光眼治疗眼压（IOP）的关键因素。。

Research Objectives

研究目标

The partnership focuses on investigating:

该合作关系的重点是调查：

• Aqueous outflow dynamics: How the procedure affects the drainage of aqueous humor.

•房水流出动力学：手术如何影响房水引流。

• Channel creation: The impact of multiple channels on IOP.

•通道创建：多个通道对IOP的影响。

• Optimal channel locations: Key to maximizing the procedure’s IOP-lowering effect.

•最佳通道位置：最大化手术降低眼压效果的关键。

World-Class Leadership in Research

世界一流的研究领导力

The research will be led by a team of internationally renowned experts:

这项研究将由国际知名专家团队领导：

• Dr. Ike Ahmed, MD, FRCSC: Director of the Crandall Center and a globally acclaimed glaucoma surgeon and innovator.

•博士。FRCSC医学博士艾克·艾哈迈德：克兰德尔中心主任，全球知名青光眼外科医生和创新者。

• Dr. Fiona McDonnell, PhD: A research scientist with extensive expertise in iPerfusion techniques.

•博士。菲奥娜·麦克唐纳博士：一位在iPerfusion技术方面拥有丰富专业知识的研究科学家。

• Dr. Ian Pitha, MD, PhD: Associate Director of the Crandall Center, bringing a wealth of knowledge in glaucoma research.

•博士。伊恩·皮塔（IanPitha），医学博士，博士：克兰德尔中心副主任，为青光眼研究带来了丰富的知识。

“Our collaboration with ViaLase perfectly aligns with the Crandall Center’s mission to transform glaucoma treatment through precision medicine and innovation,” said Dr. Ahmed. “The ViaLase procedure has the potential to provide a new paradigm in interventional glaucoma, and we are thrilled to explore its possibilities using Moran’s advanced research capabilities.”.

Ahmed博士说：“我们与ViaLase的合作与Crandall中心通过精准医学和创新改变青光眼治疗的使命完全一致。”。“ViaLase手术有可能为介入性青光眼提供一种新的范例，我们很高兴利用Moran的先进研究能力探索其可能性。”。

A Milestone for Glaucoma Care

青光眼护理的里程碑

ViaLase CEO Tibor Juhasz, PhD, emphasized the significance of this collaboration:

ViaLase首席执行官Tibor Juhasz博士强调了此次合作的重要性：

“Partnering with the Moran Eye Center, Dr. Ahmed, Prof. McDonnell, and Dr. Pitha is a significant milestone for ViaLase. Their world-class expertise in iPerfusion research techniques offers unparalleled insights into aqueous humor outflow and intraocular pressure dynamics, making them an ideal collaborator in our mission to develop innovative solutions for patients with glaucoma.

。

This capability, combined with ViaLase’s pioneering femtosecond laser platform, offers the potential for significant advancements in glaucoma care.”.

这种能力与ViaLase开创性的飞秒激光平台相结合，为青光眼护理的重大进步提供了潜力。”。

Pioneering the Future of Glaucoma Treatment

开创青光眼治疗的未来

This partnership between ViaLase and the Moran Eye Center underscores the potential for precision medicine to revolutionize glaucoma care. By leveraging advanced research technologies and expertise, the collaboration aims to set a new standard for interventional glaucoma treatment, offering hope for improved outcomes for millions of patients worldwide..

ViaLase和Moran眼科中心之间的这种合作关系强调了精准医学彻底改变青光眼护理的潜力。通过利用先进的研究技术和专业知识，该合作旨在为介入性青光眼治疗制定新标准，为全球数百万患者改善预后提供希望。。